{"gene":"AGR2","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2009,"finding":"AGR2 localizes to the ER lumen of intestinal secretory epithelial cells and forms mixed disulfide bonds with MUC2 via a cysteine residue within its thioredoxin-like domain, directly participating in mucin processing. AGR2-null mice fail to produce intestinal mucus and develop colitis.","method":"Immunolocalization (ER fractionation), mixed disulfide bond detection, AGR2 knockout mouse phenotype","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical demonstration of covalent mixed disulfide with MUC2, ER localization confirmed by fractionation, replicated loss-of-function phenotype in vivo","pmids":["19359471"],"is_preprint":false},{"year":2009,"finding":"AGR2 expression is induced by ER stress, and siRNA knockdown of AGR2 increases ER stress response in intestinal cells. AGR2-null mice show elevated ER stress, reduced MUC2, expansion of the Paneth cell compartment, and abnormal Paneth cell localization.","method":"siRNA knockdown, germline and inducible Agr2-/- mice, ER stress marker analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (germline and inducible KO) plus cell culture siRNA, replicated ER stress link across two independent labs","pmids":["20025862"],"is_preprint":false},{"year":2008,"finding":"AGR2 expression promotes cellular transformation, anchorage-independent growth, and tumor xenograft formation. RNAi-mediated reduction of AGR2 in esophageal adenocarcinoma cells decreased anchorage-independent colony growth by 82% and xenograft size by 60%.","method":"RNA interference, NIH3T3 stable transfection, xenograft assay, anchorage-independent growth assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function in vitro and in vivo, single lab","pmids":["18199544"],"is_preprint":false},{"year":2003,"finding":"Yeast two-hybrid screening identified the metastasis-associated GPI-anchored protein C4.4A and extracellular alpha-dystroglycan (DAG-1) as binding partners for AGR2 (hAG-2).","method":"Yeast two-hybrid cloning","journal":"British journal of cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid only, no validation by Co-IP or pulldown in mammalian cells reported in this abstract","pmids":["12592373"],"is_preprint":false},{"year":2011,"finding":"AGR2 localizes to both the ER lumen and the external surface of pancreatic tumor cells. Induction of AGR2 regulates ER chaperones (PDI, CALU, RCN1), ubiquitin-proteasome pathway components, and lysosomal proteases cathepsin B and D (CTSB, CTSD), including secretion of pro-CTSD. CTSB and CTSD are functional downstream targets of AGR2's proinvasive activity in vivo.","method":"Confocal microscopy, flow cytometry, proteomics/mass spectrometry, siRNA knockdown, in vivo dissemination assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (proteomics, imaging, in vivo), single lab","pmids":["21948970"],"is_preprint":false},{"year":2011,"finding":"AGR2 associates with nascent cargo proteins at ER membrane-bound ribosomes (indirectly, through nascent chains) and is involved in the maintenance of ER homeostasis. siRNA-mediated knockdown of AGR2 alters expression of ER-associated degradation (ERAD) machinery components and reduces the ability of cells to cope with acute ER stress.","method":"Proteomics of ER membrane-bound ribosomes, imaging, biochemical fractionation, siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics plus biochemical and imaging confirmation, single lab","pmids":["22025610"],"is_preprint":false},{"year":2011,"finding":"AGR2 induces expression of the EGFR ligand amphiregulin (AREG) through activation of the Hippo signaling pathway co-activator YAP1. AREG expression rescues the transformed phenotype lost when AGR2 is reduced.","method":"AGR2 overexpression/knockdown in adenocarcinoma cells, rescue experiments, Hippo pathway reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional epistasis (rescue), pathway reporter assays, single lab","pmids":["21454516"],"is_preprint":false},{"year":2011,"finding":"AGR2 function requires specifically its KTEL endoplasmic reticulum retention motif. Deletion of KTEL causes AGR2 secretion and loss of intracellular function (including induction of AREG or CDX2). Replacement of KTEL with KDEL or KSEL also abolishes function, indicating that the specific ER retention sequence—not simply ER residence—is required for AGR2 activity.","method":"KTEL deletion and substitution mutants in cell lines, functional reporter assays (amphiregulin induction, CDX2 expression), secretion assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional readout, two independent cell-line systems, single lab","pmids":["22184114"],"is_preprint":false},{"year":2012,"finding":"AGR2 localizes to the ER of MUC5AC- and MUC5B-producing airway cells and forms a complex with immature MUC5AC (detected by co-immunoprecipitation). Loss of AGR2 impairs allergen-induced MUC5AC and MUC5B overproduction and increases the proportion of mucins retained in the ER with evidence of ER stress.","method":"Immunofluorescence, co-immunoprecipitation, Agr2-/- mouse allergic airway disease model","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP demonstrates direct complex, ER localization by immunofluorescence, in vivo loss-of-function confirmation, replicates intestinal MUC2 finding in a second tissue","pmids":["22403803"],"is_preprint":false},{"year":2012,"finding":"AGR2 is both sufficient and required for MUC1 expression in pancreatic cancer cells, functioning as an ER chaperone for the cancer-associated mucin MUC1. AGR2 is also a TGF-β-responsive gene whose downregulation is SMAD4-dependent.","method":"AGR2 overexpression/knockdown in pancreatic cancer cells, SMAD4-dependent regulation assays, genetically engineered mouse models (Pdx1-Cre/LSL-KrasG12D/Smad4lox/lox heterozygous for Agr2)","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both gain- and loss-of-function in vitro plus genetic mouse model, single lab","pmids":["22945649"],"is_preprint":false},{"year":2014,"finding":"AGR2 is secreted into the gastrointestinal mucus. AGR2 cysteine-to-serine mutation (C81S) allows secretion, suggesting that modification of the single Cys residue provides a mechanism for circumventing the KTEL ER retention signal. No covalent binding of AGR2 to recombinant MUC2 N- or C-termini was detected in this study (negative result).","method":"Mucus fractionation from murine gastrointestinal tract, CHO-K1 cell culture secretion assays, C81S mutant expression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus biochemical secretion assay in tissue and cell systems, single lab","pmids":["25111734"],"is_preprint":false},{"year":2015,"finding":"AGR2 upregulates DUSP10, which subsequently inhibits p38 MAPK and prevents p53 activation by phosphorylation, establishing a pro-oncogenic signaling pathway that attenuates wild-type p53 activity.","method":"AGR2 overexpression/knockdown, DUSP10 expression analysis, p38 MAPK and p53 phosphorylation assays, breast cancer cohort analysis","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pathway dissection with multiple markers, single lab","pmids":["26733232"],"is_preprint":false},{"year":2015,"finding":"Extracellular AGR2 signals through the GPI-anchored receptor C4.4A to promote proliferation, migration, invasion, and chemoresistance of pancreatic cancer cells. AGR2-C4.4A interaction was confirmed by co-immunoprecipitation from cell lysates and with recombinant proteins; signaling requires laminins 1 or 5 and integrin β1.","method":"Co-immunoprecipitation (cell lysate and recombinant proteins), siRNA knockdown of C4.4A, blocking monoclonal antibodies, orthotopic xenograft mouse model","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with recombinant proteins, in vivo validation, single lab","pmids":["25646014"],"is_preprint":false},{"year":2016,"finding":"Extracellular AGR2 (eAGR2) is secreted as a functionally active protein independently of its thioredoxin-like CXXS domain and its KTEL ER-retention signal, and is sufficient by itself to promote acquisition of invasive and metastatic features. eAGR2 interacts with the ECM and acts as a microenvironmental regulator of epithelial tissue architecture.","method":"Domain deletion mutants, ECM interaction assays, 3D morphogenesis assays, invasion/metastasis assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mutant dissection plus ECM interaction and functional assays, single lab","pmids":["27240165"],"is_preprint":false},{"year":2016,"finding":"FOXM1 transcription factor directly binds to the AGR2 gene promoter (at the -257/-247 bp region) and transcriptionally activates AGR2. AGR2 is required for FOXM1-driven mucinous phenotype and tumor invasion in lung adenocarcinoma.","method":"ChIP, luciferase reporter assay with promoter deletions, transgenic mouse models (FOXM1 overexpression, KrasG12D), orthotopic xenografts with AGR2/FOXM1 inhibition","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct promoter binding by ChIP, functional luciferase reporter with mutagenesis, in vivo transgenic and xenograft validation","pmids":["29267283"],"is_preprint":false},{"year":2017,"finding":"AGR2 promotes EGFR translocation from the ER to the plasma membrane during pancreatitis, enabling EGFR signaling, cell proliferation, and tissue regeneration. AGR2-null mice failed to regenerate after caerulein-induced pancreatitis and died. YAP1 activation during pancreatitis was also dependent on AGR2 expression.","method":"Caerulein pancreatitis model in Agr2-/- mice, EGFR localization assays, EGFR tyrosine kinase inhibitor (AG1478), cell proliferation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout model with clear phenotype, pharmacological inhibitor orthogonal confirmation, single lab","pmids":["27764193"],"is_preprint":false},{"year":2017,"finding":"TGF-β suppresses AGR2 expression via mutually complementary Smad and ERK1/2 signaling cascades. Loss of AGR2 promotes EMT (reduced E-cadherin, increased vimentin and N-cadherin, actin reorganization), and forced re-expression of AGR2 reverses mesenchymal phenotype back to epithelial.","method":"TGF-β treatment with pathway inhibitors (PD98059 for ERK, SB431542 for TGFβR), siRNA and CRISPR/Cas9 AGR2 knockdown, EMT marker analysis by western blot, qPCR, immunofluorescence, invasion and adhesion assays","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR plus siRNA, multiple orthogonal EMT readouts, single lab","pmids":["28810836"],"is_preprint":false},{"year":2018,"finding":"Secreted AGR2 (eAGR2) promotes CRC cell migration and metastasis by elevating Wnt11 expression and triggering non-canonical Wnt signaling via CaMKII and JNK pathways. eAGR2 also antagonizes canonical Wnt/β-catenin signaling through CaMKII activation.","method":"Wnt11 knockdown, CaMKII/JNK pharmacological inhibitors, in vitro migration assays, in vivo metastasis assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological pathway dissection with in vivo validation, single lab","pmids":["29427622"],"is_preprint":false},{"year":2018,"finding":"Secreted AGR2 interacts physically with VEGFA via formation of a disulfide bond (dependent on its thioredoxin motif) to enhance VEGFR2 activity and angiogenesis. Cytosolic AGR2 stabilizes p65 protein, activates NF-κB signaling, and facilitates EMT.","method":"In vitro binding assay with purified recombinant AGR2 and VEGFA, thioredoxin motif deletion/mutation, p65 co-IP/western blot, angiogenesis assays, xenograft models","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution of disulfide bond between recombinant proteins, mutagenesis; cytosolic interaction by Co-IP, single lab","pmids":["29410027"],"is_preprint":false},{"year":2018,"finding":"AGR2 binds sequence-specifically to a peptide motif (TTIYY; consensus Tx[IL][YF][YF]) via a structural loop (amino acids 131-135, VDPSL). AGR2 stably interacts with the oncogenic receptor EpCAM via its TLIYY motif (Tyr251 of EpCAM critical for binding), demonstrated by HDX-MS, proximity ligation assay, and in vitro protein-protein interaction.","method":"Synthetic peptide affinity purification, hydrogen-deuterium exchange mass spectrometry (HDX-MS), mutant peptide library, proximity ligation assay, in vitro dose-dependent protein-protein interaction with recombinant proteins, EpCAM Tyr251Ala mutant","journal":"Molecular & cellular proteomics : MCP","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural mapping by HDX-MS, mutagenesis confirming binding residues, multiple orthogonal binding assays (affinity purification, in vitro reconstitution, PLA in cells)","pmids":["29339412"],"is_preprint":false},{"year":2018,"finding":"Loss of the AGR2 ER retention motif (KTEL) shifts AGR2 to extracellular/secreted form (eAGR2). eAGR2 promotes tumor metastasis and interacts with the mTORC2 pathway, increasing RICTOR phosphorylation at T1135. Intracellular AGR2 (iAGR2) antagonizes RICTOR phosphorylation. The two localizations have opposing effects on the Hippo pathway and spheroid formation.","method":"Protein-protein interaction screen, phosphorylation assays, in vivo metastasis models, AGR2 localization mutants","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — interaction screen with biochemical follow-up and in vivo metastasis model, single lab","pmids":["30575818"],"is_preprint":false},{"year":2019,"finding":"AGR2 dimerization state controls ER homeostasis and inflammation. TMED2 was identified as an enhancer of AGR2 dimerization. Disruption of AGR2 dimer formation (either enhancement or inhibition) leads to pro-inflammatory phenotypes: enhancing dimerization triggers autophagy-dependent processes, while inhibiting dimerization promotes secretion of AGR2 monomers as inflammatory alarm signals. In IBD/Crohn's disease, levels of AGR2 dimerization modulators are selectively deregulated.","method":"Protein-protein interaction screen, dimerization assays, autophagy assays, AGR2 secretion assays, IBD patient tissue analysis","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — interaction screen identifying TMED2, functional dimerization assays with phenotypic readouts, single lab","pmids":["31040128"],"is_preprint":false},{"year":2019,"finding":"AGR2 dimerization involves K95-K95 adducts. The N-terminal intrinsically disordered region of AGR2 stabilizes dimer formation in trans. The AGR2 dimer (Δ45-AGR2, more stable) shows greater binding activity to its interacting protein Reptin than wild-type or monomeric AGR2(E60A). Dimer stability thus controls binding to Reptin.","method":"DSS-crosslinking assay, two-site sandwich microtiter assay with DyLight800-labeled antibody, AGR2 mutants (Δ45-AGR2 stable dimer; E60A monomer), Reptin binding assays","journal":"Protein science : a publication of the Protein Society","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — chemical crosslinking, mutagenesis, functional binding assay, single lab","pmids":["23780840"],"is_preprint":false},{"year":2019,"finding":"Proteasome inhibition (MG132/bortezomib) suppresses AGR2 at mRNA and protein levels; MG132-mediated transcriptional repression is partially due to downregulation of E2F1. MG132 also facilitates degradation of polyubiquitinated AGR2 through autophagy activation via NBR1 as an autophagy receptor. The E3 ligase UBR5 conjugates K48-linked polyubiquitin chains onto K89 of AGR2.","method":"Pharmacological inhibitors (MG132, bortezomib, rapamycin), Atg5/Atg7 genetic depletion, K89 mutation, autophagy receptor (NBR1) knockdown, western blot, in vivo mouse samples","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — site-specific mutagenesis of ubiquitination site, genetic depletion of autophagy components, E3 ligase identification, single lab","pmids":["30647455"],"is_preprint":false},{"year":2021,"finding":"AGR2 directs nuclear import of RNA Polymerase II (RNAPII) via its C-terminal nuclear localization signal and binds to the largest subunit of RNAPII in a peptide motif-dependent manner. This nuclear import undermines ATR-dependent p53 activation in acinar-to-ductal metaplasia lesions. A competitive hexapeptide disrupting the AGR2-RNAPII complex blocks RNAPII nuclear import and activates DNA damage response, dramatically compromising PDAC initiation in vivo.","method":"AGR2-RNAPII Co-immunoprecipitation, nuclear import assays, pancreas-specific Agr2 knockout mouse model, competitive hexapeptide in liposomes, patient-derived organoids, RNAPII inhibitor combination studies","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct protein-protein interaction, genetic KO model, competitive peptide disruption with mechanistic and in vivo functional validation","pmids":["34303658"],"is_preprint":false},{"year":2021,"finding":"A homozygous missense variant in AGR2 in human patients causes infantile IBD (termed EAGLES). The mutant AGR2 shows reduced capacity to bind MUC2 (by co-immunoprecipitation) and reduced ability to alleviate tunicamycin-induced ER stress in HEK293T cells. Patient biopsies show reduced goblet cells, depletion of gel-forming mucins, and increased ER stress.","method":"Whole-genome sequencing, co-immunoprecipitation (AGR2-MUC2 binding with mutant vs. wild-type), ER stress assay in HEK293T cells with tunicamycin, immunohistochemistry of patient biopsies","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — human genetic variant with functional validation by Co-IP and ER stress assay, phenocopies AGR2-/- mouse, multiple orthogonal methods","pmids":["34237462"],"is_preprint":false},{"year":2021,"finding":"Intracellular AGR2 binds to KDEL receptors (KDELRs) via its KTEL motif to activate downstream Gs-PKA signaling. Activated PKA upregulates NF-κB subunit c-Rel (REL) and acetylates histone H3 at K9 (H3K9ac), promoting transcription of SNAIL and SLUG to drive EMT and CRC metastasis. AGR2 is transcriptionally upregulated by prostaglandin E2 via the EP4-PI3K-AKT pathway.","method":"Co-immunoprecipitation (AGR2-KDELR), PKA activity assays, ChIP (H3K9ac), NF-κB reporter, SNAIL/SLUG expression, AGR2 promoter analysis with EP4 inhibitors","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional signaling assays with multiple readouts, single lab","pmids":["34216690"],"is_preprint":false},{"year":2022,"finding":"Tumour-associated neutrophil (TAN)-secreted AGR2 promotes CRC cell migration by binding the heavy chain of CD98 (CD98hc) as its functional receptor, increasing xCT activity in a CD98hc-dependent manner and activating the RhoA/ROCK2 cascade. Neutrophil-specific Agr2 knockout in mice reduced CRC liver metastases. CRC-derived TGF-β1 educates peripheral neutrophils to become AGR2+ TANs.","method":"Neutrophil-specific Agr2 knockout mice, Co-immunoprecipitation (AGR2-CD98hc), xCT activity assays, RhoA/ROCK2 signaling assays, orthotopic CRC models","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic KO model plus Co-IP receptor identification and downstream signaling characterization, multiple orthogonal methods","pmids":["35086885"],"is_preprint":false},{"year":2022,"finding":"Oxidative stress-induced S-glutathionylation of AGR2 interferes with its processing and modification of MUC2 precursors, blocking synthesis of mature MUC2. NADPH (produced by G6PD) inhibits this S-glutathionylation and promotes AGR2 activity. Glutamine enhances G6PD O-GlcNAcylation, increasing G6PD homodimer formation and NADPH synthesis, which suppresses AGR2 S-glutathionylation.","method":"Burn-sepsis animal model, AGR2 S-glutathionylation assays, G6PD O-GlcNAc modification assays, G6PD homodimerization assay, NADPH measurement, MUC2 maturation assays","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — post-translational modification identified with functional consequences on AGR2 activity, single lab with multiple biochemical methods","pmids":["36565645"],"is_preprint":false},{"year":2023,"finding":"AGR2 represses IRE1β UPR transducer activity in goblet cells. In vitro, AGR2 actively destabilizes the IRE1β luminal domain dimer and forms a reversible complex with the inactive monomer. Depletion of endogenous AGR2 from goblet cells induces spontaneous IRE1β activation. AGR2 mutants lacking catalytic cysteine or carrying disease-associated H117Y mutation failed to dampen IRE1β activity. Introduction of the goblet-cell client MUC2 reversed AGR2-mediated repression of IRE1β. AGR2 had no effect on IRE1α.","method":"IRE1β/α chimera in CHO cells, in vitro reconstitution (AGR2-IRE1β luminal domain interaction), AGR2 depletion in goblet cells, catalytic cysteine and H117Y mutants, MUC2 rescue experiment","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified domains, mutagenesis confirming catalytic requirement, independent replication across two papers (PMID 38177498 and 38177501) in same journal issue","pmids":["38177498","38177501"],"is_preprint":false},{"year":2012,"finding":"Zebrafish Agr2 is expressed specifically in intestinal goblet cells and is essential for their terminal differentiation. Morpholino knockdown results in accumulation of immature goblet cells containing few mucous granules. Notably, in contrast to mouse, agr2 knockdown in zebrafish did not extensively induce UPR pathway genes (hspa5, xbp1s, chop, atf4b1).","method":"Morpholino antisense knockdown, mRNA overexpression, fluorescent whole-mount in situ hybridization, transmission electron microscopy, ER stress marker qPCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino loss-of-function with TEM ultrastructural confirmation, single lab; negative ER stress result is mechanistically informative","pmids":["22514630"],"is_preprint":false},{"year":2019,"finding":"RAD9A transcriptionally controls AGR2 by binding a partial p53 consensus sequence at position +3136 in the AGR2 5'-UTR, as demonstrated by ChIP and luciferase reporter assay. Mutation of the RAD9A-binding sequence abolished luciferase activity. Ectopic AGR2 expression in RAD9A-depleted cells restored cell migration and anchorage-independent growth phenotypes.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with binding-site mutation, stable/transient RAD9A knockdown, rescue by ectopic AGR2 expression","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct promoter occupancy by ChIP plus mutant reporter plus epistasis rescue, single lab","pmids":["30295739"],"is_preprint":false},{"year":2020,"finding":"AGR2 binds to MUC1 and induces MUC1 and HIF-1α expression in endometrial cancer cells. The pro-proliferative, migratory, and glycolytic effects of AGR2 are abolished by MUC1 knockdown, placing MUC1 downstream of AGR2 in the AGR2/MUC1/HIF-1α axis.","method":"Co-immunoprecipitation (AGR2-MUC1), MUC1 overexpression rescue of AGR2 knockdown, glycolysis assays, xenograft model","journal":"Human cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus epistasis rescue experiment, single lab","pmids":["32304027"],"is_preprint":false},{"year":2014,"finding":"AGR2 expression in breast cancer requires both FOXA1 and ERα for transcriptional regulation in tamoxifen-sensitive cells. In tamoxifen-resistant cells, constitutive AGR2 expression requires FOXA1 but loses ERα dependence, indicating a FOXA1-ERα-AGR2 regulatory loop disrupted during endocrine resistance.","method":"AGR2 knockdown in tamoxifen-sensitive and -resistant breast cancer cells, FOXA1/ERα siRNA knockdown, in vivo xenograft tumor growth, migration assays","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (FOXA1/ERα double KD), in vivo validation, single lab","pmids":["25100862"],"is_preprint":false},{"year":2022,"finding":"shRNA-mediated knockdown of AGR2 or ERp44 enhances basal DR5 oligomerization. AGR2 and ERp44 are identified as targets of Disulfide bond Disrupting Agents (DDAs) by biotinylated-DDA affinity purification, and their inhibition triggers DR4/DR5 disulfide-mediated oligomerization and caspase-8 activation in breast cancer cells.","method":"Biotinylated-DDA affinity purification, shRNA knockdown of AGR2/ERp44, DR5 oligomerization assays, ERp44 mutant expression, caspase-8 activation assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity purification identifies AGR2 as DDA target, genetic KD with functional DR5 oligomerization readout, single lab","pmids":["35247515"],"is_preprint":false}],"current_model":"AGR2 is an ER-resident protein disulfide isomerase that forms mixed disulfide bonds with gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC1) to enable their proper folding and secretion; acts as a sequence-specific peptide-binding chaperone (TTIYY motif) for client proteins including EpCAM; represses IRE1β UPR signaling in goblet cells by binding and destabilizing its luminal domain dimer; promotes nuclear import of RNA Polymerase II via its C-terminal NLS; signals intracellularly through KDEL receptors to activate Gs-PKA and downstream transcription of EMT drivers; when secreted (facilitated by C81S modification or KTEL deletion), acts extracellularly through receptors C4.4A and CD98hc to activate non-canonical Wnt, RhoA/ROCK2, and NF-κB signaling cascades promoting invasion and metastasis; and is regulated post-translationally by S-glutathionylation and K48-linked ubiquitination (by E3 ligase UBR5) at K89 with autophagic clearance via NBR1."},"narrative":{"mechanistic_narrative":"AGR2 is an endoplasmic reticulum-resident protein disulfide isomerase that enables the folding and secretion of gel-forming mucins and other secretory clients, and whose function is essential for goblet cell biology and intestinal mucus production [PMID:19359471, PMID:20025862]. It engages mucins both covalently and non-covalently: it forms mixed disulfide bonds with MUC2 through a cysteine in its thioredoxin-like domain in intestinal epithelium [PMID:19359471], complexes with immature airway mucins MUC5AC/MUC5B [PMID:22403803], and acts as a chaperone for the cancer mucin MUC1 [PMID:22945649, PMID:32304027]. Client recognition is sequence-specific—AGR2 binds a TTIYY-type peptide motif through a structural loop (residues 131-135), the basis for its stable interaction with EpCAM [PMID:29339412]. AGR2 expression is induced by ER stress and its loss elevates the unfolded protein response and disrupts ER-associated degradation [PMID:20025862, PMID:22025610]; mechanistically, AGR2 directly represses the goblet-cell UPR transducer IRE1β by destabilizing its luminal-domain dimer in a manner reversed by the client mucin MUC2, an activity requiring its catalytic cysteine [PMID:38177498, PMID:38177501]. Retention in the ER depends on a specific KTEL motif, and loss of this motif or modification of its single cysteine (C81S) shifts AGR2 to a secreted, extracellular form (eAGR2) with distinct, often opposing functions [PMID:22184114, PMID:25111734, PMID:27240165, PMID:30575818]. Intracellular AGR2 signals through KDEL receptors to activate Gs-PKA and drive transcription of EMT regulators SNAIL/SLUG [PMID:34216690] and promotes EGFR trafficking and YAP1-dependent proliferation and tissue regeneration [PMID:21454516, PMID:27764193]; it also directs nuclear import of RNA Polymerase II via a C-terminal NLS to suppress p53/DNA-damage responses during pancreatic tumor initiation [PMID:34303658]. Secreted AGR2 acts through cell-surface receptors C4.4A and CD98hc to activate non-canonical Wnt, RhoA/ROCK2 and other pro-invasive cascades and modulates the extracellular matrix to promote invasion and metastasis [PMID:25646014, PMID:35086885, PMID:29427622, PMID:27240165]. AGR2 dimerization, enhanced by TMED2 and mediated by lysine adducts, governs ER homeostasis versus inflammatory secretion [PMID:31040128, PMID:23780840], and the protein is regulated post-translationally by S-glutathionylation that blocks MUC2 maturation [PMID:36565645] and by UBR5-mediated K48 ubiquitination at K89 with autophagic clearance via NBR1 [PMID:30647455]. A homozygous AGR2 missense variant that impairs MUC2 binding and ER-stress relief causes an infantile inflammatory bowel disease (EAGLES) in humans, phenocopying the AGR2-null mouse [PMID:34237462].","teleology":[{"year":2003,"claim":"The first candidate AGR2 interactors were identified, raising the possibility that this protein engages cell-surface and metastasis-associated partners.","evidence":"Yeast two-hybrid screen identifying C4.4A and alpha-dystroglycan","pmids":["12592373"],"confidence":"Low","gaps":["Y2H only, no Co-IP or pulldown validation in mammalian cells","Functional significance of binding not established","Did not distinguish intracellular vs extracellular interaction"]},{"year":2008,"claim":"Established that AGR2 has oncogenic activity rather than being merely a marker, by showing it drives transformation and tumor growth.","evidence":"RNAi and stable overexpression in cell lines with xenograft and anchorage-independent growth assays","pmids":["18199544"],"confidence":"Medium","gaps":["Molecular mechanism of transformation not defined","Did not address ER-resident vs secreted contributions"]},{"year":2009,"claim":"Defined AGR2's core physiological function as an ER-resident enzyme that covalently processes mucins and is essential for mucus production, answering what AGR2 does in normal epithelium.","evidence":"ER fractionation, mixed disulfide detection with MUC2, and AGR2-null mouse phenotype; siRNA and inducible/germline knockouts linking AGR2 to ER stress and Paneth cells","pmids":["19359471","20025862"],"confidence":"High","gaps":["Precise cysteine residue and disulfide partner geometry on MUC2 not fully mapped","Range of mucin clients beyond MUC2 not yet defined"]},{"year":2011,"claim":"Connected AGR2's ER chaperone role to broader ER proteostasis and to oncogenic signaling outputs, and showed the KTEL retention motif itself is required for intracellular function.","evidence":"Proteomics of ER membrane-bound ribosomes and ERAD components; AREG/YAP1 and CTSB/CTSD downstream effects; KTEL deletion/substitution mutants with functional reporters","pmids":["22025610","21948970","21454516","22184114"],"confidence":"Medium","gaps":["How the specific KTEL sequence (vs KDEL/KSEL) confers function was not mechanistically resolved at this stage","Direct vs indirect engagement of nascent chains unclear"]},{"year":2012,"claim":"Generalized the mucin-chaperone role across tissues and species and to cancer-associated mucins, showing conservation of AGR2's secretory function.","evidence":"Co-IP with immature MUC5AC and airway Agr2-/- model; MUC1 gain/loss in pancreatic cancer with SMAD4-dependent regulation; zebrafish morpholino goblet-cell differentiation","pmids":["22403803","22945649","22514630"],"confidence":"Medium","gaps":["Zebrafish data showed UPR induction is not universally coupled to AGR2 loss, indicating species/context differences","Direct vs indirect MUC1 chaperoning not fully separated"]},{"year":2014,"claim":"Identified a biochemical switch—single-cysteine modification (C81S)—that permits AGR2 secretion past the KTEL signal, establishing how AGR2 escapes the ER.","evidence":"Mucus fractionation and CHO-K1 secretion assays with C81S mutant; negative covalent MUC2-terminus binding result","pmids":["25111734"],"confidence":"Medium","gaps":["Physiological trigger for C81 modification in vivo not identified","Apparent conflict with covalent MUC2 binding data not reconciled"]},{"year":2015,"claim":"Defined a receptor-based mechanism for extracellular AGR2, showing it signals through C4.4A to promote malignant phenotypes, and described an intracellular pro-survival pathway suppressing p53.","evidence":"Reciprocal Co-IP with recombinant proteins, C4.4A knockdown and blocking antibodies, orthotopic xenografts; DUSP10/p38/p53 pathway dissection","pmids":["25646014","26733232"],"confidence":"Medium","gaps":["Co-receptor requirements (laminin/integrin) not fully mechanistically dissected","Generality of C4.4A axis across cancer types untested"]},{"year":2016,"claim":"Demonstrated that secreted AGR2 is sufficient on its own, independent of its catalytic and retention domains, to confer invasive/metastatic features and to remodel the microenvironment.","evidence":"Domain-deletion mutants, ECM interaction and 3D morphogenesis assays, invasion/metastasis assays; FOXM1 ChIP and reporter with transgenic models defining transcriptional control","pmids":["27240165","29267283"],"confidence":"Medium","gaps":["Extracellular receptor(s) for catalytic-independent eAGR2 activity in this system not specified","ECM-binding partners unresolved"]},{"year":2017,"claim":"Placed AGR2 within EMT control and tissue regeneration, showing context-dependent (intracellular) roles in EGFR trafficking and epithelial identity.","evidence":"Caerulein pancreatitis in Agr2-/- mice with EGFR localization and inhibitor studies; TGF-β/Smad/ERK regulation of AGR2 with CRISPR/siRNA EMT readouts","pmids":["27764193","28810836"],"confidence":"Medium","gaps":["Direct mechanism of AGR2-driven EGFR trafficking not defined","Whether EMT effects are intracellular vs secreted AGR2 not cleanly separated"]},{"year":2018,"claim":"Mapped multiple receptor and signaling outputs for secreted and cytosolic AGR2, distinguishing localization-dependent, often opposing, functions.","evidence":"Wnt11/CaMKII/JNK dissection; recombinant VEGFA disulfide binding and p65/NF-κB Co-IP; mTORC2/RICTOR phosphorylation with localization mutants and metastasis models","pmids":["29427622","29410027","30575818"],"confidence":"Medium","gaps":["Opposing iAGR2 vs eAGR2 effects on Hippo/mTORC2 mechanistically incompletely resolved","Single-lab pathway assignments not cross-validated"]},{"year":2018,"claim":"Defined the structural basis of AGR2 client recognition, establishing it as a sequence-specific peptide-binding chaperone.","evidence":"HDX-MS structural mapping, peptide affinity purification, mutant peptide library, PLA and in vitro binding with EpCAM Tyr251 mutant","pmids":["29339412"],"confidence":"High","gaps":["Full client repertoire bearing the TTIYY motif not enumerated","Co-existence of covalent disulfide and non-covalent peptide recognition not unified structurally"]},{"year":2019,"claim":"Established that AGR2 dimerization state is a regulatory switch between ER homeostasis and inflammatory secretion, and defined its post-translational degradation route.","evidence":"TMED2 interaction screen and dimerization assays with IBD tissue; DSS-crosslinking, K95 adduct and Reptin binding mutants; UBR5/K89 ubiquitination, NBR1-autophagy and proteasome-inhibitor studies; RAD9A transcriptional control","pmids":["31040128","23780840","30647455","30295739"],"confidence":"Medium","gaps":["How dimerization is sensed and reversed in vivo unclear","Relationship between K89 ubiquitination, K95 dimer adducts, and secretion not integrated"]},{"year":2021,"claim":"Revealed unexpected nuclear and KDELR-coupled signaling functions, showing AGR2 controls RNAPII import and PKA-driven EMT transcription, and confirmed human disease causation.","evidence":"AGR2-RNAPII Co-IP, nuclear import assays, pancreas-specific KO and competitive hexapeptide; AGR2-KDELR Co-IP with PKA/NF-κB/H3K9ac readouts; whole-genome sequencing of EAGLES patients with functional MUC2-binding and ER-stress validation","pmids":["34303658","34216690","34237462"],"confidence":"High","gaps":["How the same KTEL motif serves both KDELR signaling and ER retention not fully reconciled","Structural basis of RNAPII NLS-mediated import undefined"]},{"year":2022,"claim":"Extended AGR2 biology to the tumor microenvironment and defined CD98hc as an extracellular receptor, plus a redox post-translational control of mucin maturation.","evidence":"Neutrophil-specific Agr2 KO, AGR2-CD98hc Co-IP, xCT/RhoA/ROCK2 assays; AGR2 S-glutathionylation and G6PD/NADPH axis in burn-sepsis model; AGR2/ERp44 as DDA targets controlling DR5 oligomerization; AGR2-MUC1-HIF1α axis","pmids":["35086885","36565645","35247515","32304027"],"confidence":"Medium","gaps":["Cross-talk between AGR2's pro-survival disulfide functions and apoptosis (DR5) needs integration","In vivo relevance of S-glutathionylation beyond burn-sepsis model untested"]},{"year":2023,"claim":"Resolved a direct mechanism by which AGR2 governs the goblet-cell UPR, showing it actively represses IRE1β and links client load to UPR signaling.","evidence":"IRE1β/α chimeras in CHO cells, in vitro reconstitution of AGR2-IRE1β luminal-domain destabilization, catalytic-cysteine and H117Y mutants, MUC2 rescue; independent replication across two papers","pmids":["38177498","38177501"],"confidence":"High","gaps":["Structural detail of AGR2 destabilizing the IRE1β dimer not fully resolved","How disease mutations alter this specific repression in vivo not directly tested"]},{"year":null,"claim":"How AGR2's multiple, sometimes opposing, intracellular (ER chaperone, IRE1β repressor, KDELR signaler, RNAPII importer) and extracellular (C4.4A/CD98hc receptor agonist) activities are coordinated by localization, dimerization, and redox state within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking modification state (C81/C95/K89, glutathionylation) to functional partitioning","Structural basis for nuclear import and KDELR signaling undefined","Receptor specificity determinants for eAGR2 not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016853","term_label":"isomerase activity","supporting_discovery_ids":[0,29]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[8,9,19,29]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,19,29]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[12,26,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[29,21]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,1,5,8]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[10,13,12,27]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[24]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,8,9,19]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[1,5,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,17,26,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,2,24]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[24,26]}],"complexes":[],"partners":["MUC2","MUC5AC","MUC1","EPCAM","IRE1B","C4.4A","CD98HC","TMED2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95994","full_name":"Anterior gradient protein 2 homolog","aliases":["HPC8","Secreted cement gland protein XAG-2 homolog"],"length_aa":175,"mass_kda":20.0,"function":"Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells (By similarity). Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth. Promotes cell adhesion (PubMed:23274113)","subcellular_location":"Secreted; Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/O95994/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AGR2","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AGR2","total_profiled":1310},"omim":[{"mim_id":"620233","title":"RESPIRATORY INFECTIONS, RECURRENT, AND FAILURE TO THRIVE WITH OR WITHOUT DIARRHEA; RIFTD","url":"https://www.omim.org/entry/620233"},{"mim_id":"609484","title":"LY6/PLAUR DOMAIN-CONTAINING PROTEIN 3; LYPD3","url":"https://www.omim.org/entry/609484"},{"mim_id":"609482","title":"ANTERIOR GRADIENT 3, PROTEIN DISULPHIDE ISOMERASE FAMILY MEMBER; AGR3","url":"https://www.omim.org/entry/609482"},{"mim_id":"606358","title":"ANTERIOR GRADIENT 2, PROTEIN DISULPHIDE ISOMERASE FAMILY MEMBER; AGR2","url":"https://www.omim.org/entry/606358"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Endoplasmic reticulum","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"cervix","ntpm":600.4},{"tissue":"intestine","ntpm":1148.3},{"tissue":"stomach 1","ntpm":1323.9}],"url":"https://www.proteinatlas.org/search/AGR2"},"hgnc":{"alias_symbol":["XAG-2","HAG-2","AG2","PDIA17"],"prev_symbol":[]},"alphafold":{"accession":"O95994","domains":[{"cath_id":"3.40.30.10","chopping":"49-167","consensus_level":"high","plddt":97.0745,"start":49,"end":167}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95994","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95994-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95994-F1-predicted_aligned_error_v6.png","plddt_mean":86.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AGR2","jax_strain_url":"https://www.jax.org/strain/search?query=AGR2"},"sequence":{"accession":"O95994","fasta_url":"https://rest.uniprot.org/uniprotkb/O95994.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95994/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95994"}},"corpus_meta":[{"pmid":"19359471","id":"PMC_19359471","title":"The protein disulfide isomerase AGR2 is essential for production of intestinal mucus.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19359471","citation_count":336,"is_preprint":false},{"pmid":"20025862","id":"PMC_20025862","title":"Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20025862","citation_count":181,"is_preprint":false},{"pmid":"18199544","id":"PMC_18199544","title":"The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18199544","citation_count":176,"is_preprint":false},{"pmid":"31856843","id":"PMC_31856843","title":"LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription.","date":"2019","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31856843","citation_count":170,"is_preprint":false},{"pmid":"12592373","id":"PMC_12592373","title":"hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12592373","citation_count":158,"is_preprint":false},{"pmid":"9790916","id":"PMC_9790916","title":"hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9790916","citation_count":143,"is_preprint":false},{"pmid":"9533957","id":"PMC_9533957","title":"Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2.","date":"1998","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9533957","citation_count":142,"is_preprint":false},{"pmid":"21948970","id":"PMC_21948970","title":"AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21948970","citation_count":125,"is_preprint":false},{"pmid":"15834940","id":"PMC_15834940","title":"AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer.","date":"2005","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15834940","citation_count":120,"is_preprint":false},{"pmid":"16222343","id":"PMC_16222343","title":"Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease.","date":"2006","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16222343","citation_count":110,"is_preprint":false},{"pmid":"22025610","id":"PMC_22025610","title":"Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22025610","citation_count":104,"is_preprint":false},{"pmid":"35086885","id":"PMC_35086885","title":"Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT.","date":"2022","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/35086885","citation_count":103,"is_preprint":false},{"pmid":"22403803","id":"PMC_22403803","title":"AGR2 is induced in asthma and promotes allergen-induced mucin overproduction.","date":"2012","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22403803","citation_count":100,"is_preprint":false},{"pmid":"23635006","id":"PMC_23635006","title":"The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker.","date":"2013","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/23635006","citation_count":99,"is_preprint":false},{"pmid":"27941872","id":"PMC_27941872","title":"ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27941872","citation_count":86,"is_preprint":false},{"pmid":"29107102","id":"PMC_29107102","title":"miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29107102","citation_count":84,"is_preprint":false},{"pmid":"21200134","id":"PMC_21200134","title":"AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration.","date":"2011","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21200134","citation_count":82,"is_preprint":false},{"pmid":"21454516","id":"PMC_21454516","title":"The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454516","citation_count":80,"is_preprint":false},{"pmid":"20945500","id":"PMC_20945500","title":"The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection.","date":"2010","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/20945500","citation_count":80,"is_preprint":false},{"pmid":"16598187","id":"PMC_16598187","title":"Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16598187","citation_count":77,"is_preprint":false},{"pmid":"27240165","id":"PMC_27240165","title":"Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27240165","citation_count":75,"is_preprint":false},{"pmid":"17455144","id":"PMC_17455144","title":"Expression of AGR2 in non small cell lung cancer.","date":"2007","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/17455144","citation_count":73,"is_preprint":false},{"pmid":"30647455","id":"PMC_30647455","title":"Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30647455","citation_count":67,"is_preprint":false},{"pmid":"31040128","id":"PMC_31040128","title":"Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation.","date":"2019","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31040128","citation_count":65,"is_preprint":false},{"pmid":"25111734","id":"PMC_25111734","title":"AGR2, an endoplasmic reticulum protein, is secreted into the gastrointestinal mucus.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25111734","citation_count":64,"is_preprint":false},{"pmid":"17694278","id":"PMC_17694278","title":"Physiological stress induces the metastasis marker AGR2 in breast cancer cells.","date":"2007","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17694278","citation_count":63,"is_preprint":false},{"pmid":"25646014","id":"PMC_25646014","title":"New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice.","date":"2015","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25646014","citation_count":59,"is_preprint":false},{"pmid":"22945649","id":"PMC_22945649","title":"AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22945649","citation_count":59,"is_preprint":false},{"pmid":"34237462","id":"PMC_34237462","title":"Human AGR2 Deficiency Causes Mucus Barrier Dysfunction and Infantile Inflammatory Bowel Disease.","date":"2021","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34237462","citation_count":58,"is_preprint":false},{"pmid":"22911164","id":"PMC_22911164","title":"Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.","date":"2012","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/22911164","citation_count":55,"is_preprint":false},{"pmid":"24251762","id":"PMC_24251762","title":"A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/24251762","citation_count":53,"is_preprint":false},{"pmid":"29267283","id":"PMC_29267283","title":"FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29267283","citation_count":52,"is_preprint":false},{"pmid":"21144054","id":"PMC_21144054","title":"Differential expression of anterior gradient gene AGR2 in prostate cancer.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21144054","citation_count":51,"is_preprint":false},{"pmid":"29427622","id":"PMC_29427622","title":"Secreted AGR2 promotes invasion of colorectal cancer cells via Wnt11-mediated non-canonical Wnt signaling.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29427622","citation_count":49,"is_preprint":false},{"pmid":"26733232","id":"PMC_26733232","title":"AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.","date":"2015","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26733232","citation_count":47,"is_preprint":false},{"pmid":"22072305","id":"PMC_22072305","title":"Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine.","date":"2011","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/22072305","citation_count":47,"is_preprint":false},{"pmid":"30991076","id":"PMC_30991076","title":"Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30991076","citation_count":45,"is_preprint":false},{"pmid":"22184114","id":"PMC_22184114","title":"AGR2 gene function requires a unique endoplasmic reticulum localization motif.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22184114","citation_count":45,"is_preprint":false},{"pmid":"33005802","id":"PMC_33005802","title":"Secretion of pro-oncogenic AGR2 protein in cancer.","date":"2020","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/33005802","citation_count":43,"is_preprint":false},{"pmid":"25666661","id":"PMC_25666661","title":"The role of AGR2 and AGR3 in cancer: similar but not identical.","date":"2015","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25666661","citation_count":42,"is_preprint":false},{"pmid":"23712868","id":"PMC_23712868","title":"AGR2 expression is regulated by HIF-1 and contributes to growth and angiogenesis of glioblastoma.","date":"2013","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/23712868","citation_count":42,"is_preprint":false},{"pmid":"22605983","id":"PMC_22605983","title":"Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer.","date":"2012","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22605983","citation_count":42,"is_preprint":false},{"pmid":"28339048","id":"PMC_28339048","title":"AGR2 ameliorates tumor necrosis factor-α-induced epithelial barrier dysfunction via suppression of NF-κB p65-mediated MLCK/p-MLC pathway activation.","date":"2017","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28339048","citation_count":42,"is_preprint":false},{"pmid":"22514630","id":"PMC_22514630","title":"Zebrafish Agr2 is required for terminal differentiation of intestinal goblet cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22514630","citation_count":41,"is_preprint":false},{"pmid":"36565645","id":"PMC_36565645","title":"Glutamine promotes O-GlcNAcylation of G6PD and inhibits AGR2 S-glutathionylation to maintain the intestinal mucus barrier in burned septic mice.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36565645","citation_count":39,"is_preprint":false},{"pmid":"25488752","id":"PMC_25488752","title":"Agr2 mediates paracrine effects on stromal fibroblasts that promote invasion by gastric signet-ring carcinoma cells.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25488752","citation_count":39,"is_preprint":false},{"pmid":"33223849","id":"PMC_33223849","title":"CircPVT1 Promoted the Progression of Breast Cancer by Regulating MiR-29a-3p-Mediated AGR2-HIF-1α Pathway.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33223849","citation_count":39,"is_preprint":false},{"pmid":"29410027","id":"PMC_29410027","title":"Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-κB pathway.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29410027","citation_count":39,"is_preprint":false},{"pmid":"31178140","id":"PMC_31178140","title":"AGR2 is a target of canonical Wnt/β-catenin signaling and is important for stemness maintenance in colorectal cancer stem cells.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31178140","citation_count":38,"is_preprint":false},{"pmid":"27322206","id":"PMC_27322206","title":"MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27322206","citation_count":37,"is_preprint":false},{"pmid":"28810836","id":"PMC_28810836","title":"Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28810836","citation_count":37,"is_preprint":false},{"pmid":"17175205","id":"PMC_17175205","title":"Characterization of the agr2 gene, a homologue of X. laevis anterior gradient 2, from the zebrafish, Danio rerio.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/17175205","citation_count":37,"is_preprint":false},{"pmid":"34964205","id":"PMC_34964205","title":"Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.","date":"2021","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34964205","citation_count":35,"is_preprint":false},{"pmid":"25100862","id":"PMC_25100862","title":"Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25100862","citation_count":34,"is_preprint":false},{"pmid":"22467239","id":"PMC_22467239","title":"Knockdown of AGR2 induces cellular senescence in prostate cancer cells.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22467239","citation_count":33,"is_preprint":false},{"pmid":"22659167","id":"PMC_22659167","title":"CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma.","date":"2012","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22659167","citation_count":33,"is_preprint":false},{"pmid":"34216690","id":"PMC_34216690","title":"Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34216690","citation_count":32,"is_preprint":false},{"pmid":"30575818","id":"PMC_30575818","title":"Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30575818","citation_count":32,"is_preprint":false},{"pmid":"23209296","id":"PMC_23209296","title":"Loss of anterior gradient 2 (Agr2) expression results in hyperplasia and defective lineage maturation in the murine stomach.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23209296","citation_count":31,"is_preprint":false},{"pmid":"38177498","id":"PMC_38177498","title":"The IRE1β-mediated unfolded protein response is repressed by the chaperone AGR2 in mucin producing cells.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/38177498","citation_count":30,"is_preprint":false},{"pmid":"23348903","id":"PMC_23348903","title":"Prostate cancer cell phenotypes based on AGR2 and CD10 expression.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23348903","citation_count":29,"is_preprint":false},{"pmid":"32304027","id":"PMC_32304027","title":"AGR2-induced glucose metabolism facilitated the progression of endometrial carcinoma via enhancing the MUC1/HIF-1α pathway.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32304027","citation_count":29,"is_preprint":false},{"pmid":"20299546","id":"PMC_20299546","title":"2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2.","date":"2010","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/20299546","citation_count":29,"is_preprint":false},{"pmid":"24167368","id":"PMC_24167368","title":"AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients.","date":"2013","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/24167368","citation_count":29,"is_preprint":false},{"pmid":"22819674","id":"PMC_22819674","title":"The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22819674","citation_count":27,"is_preprint":false},{"pmid":"30238476","id":"PMC_30238476","title":"The role of protein disulphide isomerase AGR2 in the tumour niche.","date":"2018","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/30238476","citation_count":27,"is_preprint":false},{"pmid":"34873459","id":"PMC_34873459","title":"From development to cancer - an ever-increasing role of AGR2.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34873459","citation_count":25,"is_preprint":false},{"pmid":"24490732","id":"PMC_24490732","title":"AGR2, ERp57/GRP58, and some other human protein disulfide isomerases.","date":"2013","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/24490732","citation_count":24,"is_preprint":false},{"pmid":"30055941","id":"PMC_30055941","title":"Knockdown of AGR2 induces cell apoptosis and reduces chemotherapy resistance of pancreatic cancer cells with the involvement of ERK/AKT axis.","date":"2018","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/30055941","citation_count":24,"is_preprint":false},{"pmid":"33413231","id":"PMC_33413231","title":"Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells.","date":"2021","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33413231","citation_count":24,"is_preprint":false},{"pmid":"38177501","id":"PMC_38177501","title":"Activation of goblet-cell stress sensor IRE1β is controlled by the mucin chaperone AGR2.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/38177501","citation_count":24,"is_preprint":false},{"pmid":"24920423","id":"PMC_24920423","title":"Aberrant hypomethylation-mediated AGR2 overexpression induces an aggressive phenotype in ovarian cancer cells.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24920423","citation_count":23,"is_preprint":false},{"pmid":"23094510","id":"PMC_23094510","title":"AGR2 as a potential biomarker of human lung adenocarcinoma.","date":"2012","source":"Osaka city medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23094510","citation_count":23,"is_preprint":false},{"pmid":"34656689","id":"PMC_34656689","title":"125I seeds inhibit proliferation and promote apoptosis in cholangiocarcinoma cells by regulating the AGR2-mediated p38 MAPK pathway.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34656689","citation_count":22,"is_preprint":false},{"pmid":"35013529","id":"PMC_35013529","title":"Induction of cancer cell stemness in glioma through glycolysis and the long noncoding RNA HULC-activated FOXM1/AGR2/HIF-1α axis.","date":"2022","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35013529","citation_count":22,"is_preprint":false},{"pmid":"32493835","id":"PMC_32493835","title":"Long noncoding RNA LINC00460 conduces to tumor growth and metastasis of hepatocellular carcinoma through miR-342-3p-dependent AGR2 up-regulation.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32493835","citation_count":22,"is_preprint":false},{"pmid":"25956506","id":"PMC_25956506","title":"Induction of anterior gradient 2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25956506","citation_count":22,"is_preprint":false},{"pmid":"27764193","id":"PMC_27764193","title":"Anterior Gradient 2 (AGR2) Induced Epidermal Growth Factor Receptor (EGFR) Signaling Is Essential for Murine Pancreatitis-Associated Tissue Regeneration.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27764193","citation_count":21,"is_preprint":false},{"pmid":"32606743","id":"PMC_32606743","title":"FOXA1 Promotes Cell Proliferation and Suppresses Apoptosis in HCC by Directly Regulating miR-212-3p/FOXA1/AGR2 Signaling Pathway.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32606743","citation_count":21,"is_preprint":false},{"pmid":"26894971","id":"PMC_26894971","title":"Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26894971","citation_count":21,"is_preprint":false},{"pmid":"34303658","id":"PMC_34303658","title":"AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.","date":"2021","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/34303658","citation_count":20,"is_preprint":false},{"pmid":"23222243","id":"PMC_23222243","title":"AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation.","date":"2013","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23222243","citation_count":20,"is_preprint":false},{"pmid":"22828706","id":"PMC_22828706","title":"Proteomic study explores AGR2 as pro-metastatic protein in HCC.","date":"2012","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/22828706","citation_count":20,"is_preprint":false},{"pmid":"32234873","id":"PMC_32234873","title":"Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.","date":"2020","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32234873","citation_count":20,"is_preprint":false},{"pmid":"29339412","id":"PMC_29339412","title":"The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM.","date":"2018","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/29339412","citation_count":20,"is_preprint":false},{"pmid":"23780840","id":"PMC_23780840","title":"Development of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein.","date":"2013","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/23780840","citation_count":20,"is_preprint":false},{"pmid":"35247515","id":"PMC_35247515","title":"Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35247515","citation_count":19,"is_preprint":false},{"pmid":"27283903","id":"PMC_27283903","title":"Cancer-secreted AGR2 induces programmed cell death in normal cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27283903","citation_count":18,"is_preprint":false},{"pmid":"28337279","id":"PMC_28337279","title":"AGR2 promotes the proliferation, migration and regulates epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28337279","citation_count":18,"is_preprint":false},{"pmid":"32570918","id":"PMC_32570918","title":"ZEB1/miR-200c/AGR2: A New Regulatory Loop Modulating the Epithelial-Mesenchymal Transition in Lung Adenocarcinomas.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32570918","citation_count":18,"is_preprint":false},{"pmid":"29845750","id":"PMC_29845750","title":"Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma.","date":"2018","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29845750","citation_count":18,"is_preprint":false},{"pmid":"28092730","id":"PMC_28092730","title":"Serum AGR2 as a useful biomarker for pituitary adenomas.","date":"2017","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/28092730","citation_count":17,"is_preprint":false},{"pmid":"28402678","id":"PMC_28402678","title":"Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.","date":"2017","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28402678","citation_count":17,"is_preprint":false},{"pmid":"33278424","id":"PMC_33278424","title":"Extracellular AGR2 triggers lung tumour cell proliferation through repression of p21CIP1.","date":"2020","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33278424","citation_count":16,"is_preprint":false},{"pmid":"30295739","id":"PMC_30295739","title":"RAD9A promotes metastatic phenotypes through transcriptional regulation of anterior gradient 2 (AGR2).","date":"2019","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30295739","citation_count":16,"is_preprint":false},{"pmid":"32184630","id":"PMC_32184630","title":"Long Noncoding RNA LINC00460 Promotes Hepatocellular Carcinoma Progression via Regulation of miR-342-3p/AGR2 Axis.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32184630","citation_count":16,"is_preprint":false},{"pmid":"31436390","id":"PMC_31436390","title":"TP53 mediated miR-3647-5p prevents progression of cervical carcinoma by targeting AGR2.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31436390","citation_count":16,"is_preprint":false},{"pmid":"37197416","id":"PMC_37197416","title":"AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37197416","citation_count":15,"is_preprint":false},{"pmid":"36384110","id":"PMC_36384110","title":"Agr2-associated ER stress promotes adherent-invasive E. coli dysbiosis and triggers CD103+ dendritic cell IL-23-dependent ileocolitis.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36384110","citation_count":15,"is_preprint":false},{"pmid":"28238761","id":"PMC_28238761","title":"AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients.","date":"2017","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28238761","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49619,"output_tokens":9186,"usd":0.143323,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19160,"output_tokens":5911,"usd":0.121788,"stage2_stop_reason":"end_turn"},"total_usd":0.265111,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"AGR2 localizes to the ER lumen of intestinal secretory epithelial cells and forms mixed disulfide bonds with MUC2 via a cysteine residue within its thioredoxin-like domain, directly participating in mucin processing. AGR2-null mice fail to produce intestinal mucus and develop colitis.\",\n      \"method\": \"Immunolocalization (ER fractionation), mixed disulfide bond detection, AGR2 knockout mouse phenotype\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical demonstration of covalent mixed disulfide with MUC2, ER localization confirmed by fractionation, replicated loss-of-function phenotype in vivo\",\n      \"pmids\": [\"19359471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"AGR2 expression is induced by ER stress, and siRNA knockdown of AGR2 increases ER stress response in intestinal cells. AGR2-null mice show elevated ER stress, reduced MUC2, expansion of the Paneth cell compartment, and abnormal Paneth cell localization.\",\n      \"method\": \"siRNA knockdown, germline and inducible Agr2-/- mice, ER stress marker analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (germline and inducible KO) plus cell culture siRNA, replicated ER stress link across two independent labs\",\n      \"pmids\": [\"20025862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AGR2 expression promotes cellular transformation, anchorage-independent growth, and tumor xenograft formation. RNAi-mediated reduction of AGR2 in esophageal adenocarcinoma cells decreased anchorage-independent colony growth by 82% and xenograft size by 60%.\",\n      \"method\": \"RNA interference, NIH3T3 stable transfection, xenograft assay, anchorage-independent growth assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function in vitro and in vivo, single lab\",\n      \"pmids\": [\"18199544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Yeast two-hybrid screening identified the metastasis-associated GPI-anchored protein C4.4A and extracellular alpha-dystroglycan (DAG-1) as binding partners for AGR2 (hAG-2).\",\n      \"method\": \"Yeast two-hybrid cloning\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid only, no validation by Co-IP or pulldown in mammalian cells reported in this abstract\",\n      \"pmids\": [\"12592373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGR2 localizes to both the ER lumen and the external surface of pancreatic tumor cells. Induction of AGR2 regulates ER chaperones (PDI, CALU, RCN1), ubiquitin-proteasome pathway components, and lysosomal proteases cathepsin B and D (CTSB, CTSD), including secretion of pro-CTSD. CTSB and CTSD are functional downstream targets of AGR2's proinvasive activity in vivo.\",\n      \"method\": \"Confocal microscopy, flow cytometry, proteomics/mass spectrometry, siRNA knockdown, in vivo dissemination assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (proteomics, imaging, in vivo), single lab\",\n      \"pmids\": [\"21948970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGR2 associates with nascent cargo proteins at ER membrane-bound ribosomes (indirectly, through nascent chains) and is involved in the maintenance of ER homeostasis. siRNA-mediated knockdown of AGR2 alters expression of ER-associated degradation (ERAD) machinery components and reduces the ability of cells to cope with acute ER stress.\",\n      \"method\": \"Proteomics of ER membrane-bound ribosomes, imaging, biochemical fractionation, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics plus biochemical and imaging confirmation, single lab\",\n      \"pmids\": [\"22025610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGR2 induces expression of the EGFR ligand amphiregulin (AREG) through activation of the Hippo signaling pathway co-activator YAP1. AREG expression rescues the transformed phenotype lost when AGR2 is reduced.\",\n      \"method\": \"AGR2 overexpression/knockdown in adenocarcinoma cells, rescue experiments, Hippo pathway reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional epistasis (rescue), pathway reporter assays, single lab\",\n      \"pmids\": [\"21454516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGR2 function requires specifically its KTEL endoplasmic reticulum retention motif. Deletion of KTEL causes AGR2 secretion and loss of intracellular function (including induction of AREG or CDX2). Replacement of KTEL with KDEL or KSEL also abolishes function, indicating that the specific ER retention sequence—not simply ER residence—is required for AGR2 activity.\",\n      \"method\": \"KTEL deletion and substitution mutants in cell lines, functional reporter assays (amphiregulin induction, CDX2 expression), secretion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional readout, two independent cell-line systems, single lab\",\n      \"pmids\": [\"22184114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AGR2 localizes to the ER of MUC5AC- and MUC5B-producing airway cells and forms a complex with immature MUC5AC (detected by co-immunoprecipitation). Loss of AGR2 impairs allergen-induced MUC5AC and MUC5B overproduction and increases the proportion of mucins retained in the ER with evidence of ER stress.\",\n      \"method\": \"Immunofluorescence, co-immunoprecipitation, Agr2-/- mouse allergic airway disease model\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP demonstrates direct complex, ER localization by immunofluorescence, in vivo loss-of-function confirmation, replicates intestinal MUC2 finding in a second tissue\",\n      \"pmids\": [\"22403803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AGR2 is both sufficient and required for MUC1 expression in pancreatic cancer cells, functioning as an ER chaperone for the cancer-associated mucin MUC1. AGR2 is also a TGF-β-responsive gene whose downregulation is SMAD4-dependent.\",\n      \"method\": \"AGR2 overexpression/knockdown in pancreatic cancer cells, SMAD4-dependent regulation assays, genetically engineered mouse models (Pdx1-Cre/LSL-KrasG12D/Smad4lox/lox heterozygous for Agr2)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both gain- and loss-of-function in vitro plus genetic mouse model, single lab\",\n      \"pmids\": [\"22945649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AGR2 is secreted into the gastrointestinal mucus. AGR2 cysteine-to-serine mutation (C81S) allows secretion, suggesting that modification of the single Cys residue provides a mechanism for circumventing the KTEL ER retention signal. No covalent binding of AGR2 to recombinant MUC2 N- or C-termini was detected in this study (negative result).\",\n      \"method\": \"Mucus fractionation from murine gastrointestinal tract, CHO-K1 cell culture secretion assays, C81S mutant expression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus biochemical secretion assay in tissue and cell systems, single lab\",\n      \"pmids\": [\"25111734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AGR2 upregulates DUSP10, which subsequently inhibits p38 MAPK and prevents p53 activation by phosphorylation, establishing a pro-oncogenic signaling pathway that attenuates wild-type p53 activity.\",\n      \"method\": \"AGR2 overexpression/knockdown, DUSP10 expression analysis, p38 MAPK and p53 phosphorylation assays, breast cancer cohort analysis\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pathway dissection with multiple markers, single lab\",\n      \"pmids\": [\"26733232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Extracellular AGR2 signals through the GPI-anchored receptor C4.4A to promote proliferation, migration, invasion, and chemoresistance of pancreatic cancer cells. AGR2-C4.4A interaction was confirmed by co-immunoprecipitation from cell lysates and with recombinant proteins; signaling requires laminins 1 or 5 and integrin β1.\",\n      \"method\": \"Co-immunoprecipitation (cell lysate and recombinant proteins), siRNA knockdown of C4.4A, blocking monoclonal antibodies, orthotopic xenograft mouse model\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with recombinant proteins, in vivo validation, single lab\",\n      \"pmids\": [\"25646014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Extracellular AGR2 (eAGR2) is secreted as a functionally active protein independently of its thioredoxin-like CXXS domain and its KTEL ER-retention signal, and is sufficient by itself to promote acquisition of invasive and metastatic features. eAGR2 interacts with the ECM and acts as a microenvironmental regulator of epithelial tissue architecture.\",\n      \"method\": \"Domain deletion mutants, ECM interaction assays, 3D morphogenesis assays, invasion/metastasis assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mutant dissection plus ECM interaction and functional assays, single lab\",\n      \"pmids\": [\"27240165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXM1 transcription factor directly binds to the AGR2 gene promoter (at the -257/-247 bp region) and transcriptionally activates AGR2. AGR2 is required for FOXM1-driven mucinous phenotype and tumor invasion in lung adenocarcinoma.\",\n      \"method\": \"ChIP, luciferase reporter assay with promoter deletions, transgenic mouse models (FOXM1 overexpression, KrasG12D), orthotopic xenografts with AGR2/FOXM1 inhibition\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct promoter binding by ChIP, functional luciferase reporter with mutagenesis, in vivo transgenic and xenograft validation\",\n      \"pmids\": [\"29267283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AGR2 promotes EGFR translocation from the ER to the plasma membrane during pancreatitis, enabling EGFR signaling, cell proliferation, and tissue regeneration. AGR2-null mice failed to regenerate after caerulein-induced pancreatitis and died. YAP1 activation during pancreatitis was also dependent on AGR2 expression.\",\n      \"method\": \"Caerulein pancreatitis model in Agr2-/- mice, EGFR localization assays, EGFR tyrosine kinase inhibitor (AG1478), cell proliferation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout model with clear phenotype, pharmacological inhibitor orthogonal confirmation, single lab\",\n      \"pmids\": [\"27764193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TGF-β suppresses AGR2 expression via mutually complementary Smad and ERK1/2 signaling cascades. Loss of AGR2 promotes EMT (reduced E-cadherin, increased vimentin and N-cadherin, actin reorganization), and forced re-expression of AGR2 reverses mesenchymal phenotype back to epithelial.\",\n      \"method\": \"TGF-β treatment with pathway inhibitors (PD98059 for ERK, SB431542 for TGFβR), siRNA and CRISPR/Cas9 AGR2 knockdown, EMT marker analysis by western blot, qPCR, immunofluorescence, invasion and adhesion assays\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR plus siRNA, multiple orthogonal EMT readouts, single lab\",\n      \"pmids\": [\"28810836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Secreted AGR2 (eAGR2) promotes CRC cell migration and metastasis by elevating Wnt11 expression and triggering non-canonical Wnt signaling via CaMKII and JNK pathways. eAGR2 also antagonizes canonical Wnt/β-catenin signaling through CaMKII activation.\",\n      \"method\": \"Wnt11 knockdown, CaMKII/JNK pharmacological inhibitors, in vitro migration assays, in vivo metastasis assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological pathway dissection with in vivo validation, single lab\",\n      \"pmids\": [\"29427622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Secreted AGR2 interacts physically with VEGFA via formation of a disulfide bond (dependent on its thioredoxin motif) to enhance VEGFR2 activity and angiogenesis. Cytosolic AGR2 stabilizes p65 protein, activates NF-κB signaling, and facilitates EMT.\",\n      \"method\": \"In vitro binding assay with purified recombinant AGR2 and VEGFA, thioredoxin motif deletion/mutation, p65 co-IP/western blot, angiogenesis assays, xenograft models\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution of disulfide bond between recombinant proteins, mutagenesis; cytosolic interaction by Co-IP, single lab\",\n      \"pmids\": [\"29410027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AGR2 binds sequence-specifically to a peptide motif (TTIYY; consensus Tx[IL][YF][YF]) via a structural loop (amino acids 131-135, VDPSL). AGR2 stably interacts with the oncogenic receptor EpCAM via its TLIYY motif (Tyr251 of EpCAM critical for binding), demonstrated by HDX-MS, proximity ligation assay, and in vitro protein-protein interaction.\",\n      \"method\": \"Synthetic peptide affinity purification, hydrogen-deuterium exchange mass spectrometry (HDX-MS), mutant peptide library, proximity ligation assay, in vitro dose-dependent protein-protein interaction with recombinant proteins, EpCAM Tyr251Ala mutant\",\n      \"journal\": \"Molecular & cellular proteomics : MCP\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural mapping by HDX-MS, mutagenesis confirming binding residues, multiple orthogonal binding assays (affinity purification, in vitro reconstitution, PLA in cells)\",\n      \"pmids\": [\"29339412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of the AGR2 ER retention motif (KTEL) shifts AGR2 to extracellular/secreted form (eAGR2). eAGR2 promotes tumor metastasis and interacts with the mTORC2 pathway, increasing RICTOR phosphorylation at T1135. Intracellular AGR2 (iAGR2) antagonizes RICTOR phosphorylation. The two localizations have opposing effects on the Hippo pathway and spheroid formation.\",\n      \"method\": \"Protein-protein interaction screen, phosphorylation assays, in vivo metastasis models, AGR2 localization mutants\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — interaction screen with biochemical follow-up and in vivo metastasis model, single lab\",\n      \"pmids\": [\"30575818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AGR2 dimerization state controls ER homeostasis and inflammation. TMED2 was identified as an enhancer of AGR2 dimerization. Disruption of AGR2 dimer formation (either enhancement or inhibition) leads to pro-inflammatory phenotypes: enhancing dimerization triggers autophagy-dependent processes, while inhibiting dimerization promotes secretion of AGR2 monomers as inflammatory alarm signals. In IBD/Crohn's disease, levels of AGR2 dimerization modulators are selectively deregulated.\",\n      \"method\": \"Protein-protein interaction screen, dimerization assays, autophagy assays, AGR2 secretion assays, IBD patient tissue analysis\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — interaction screen identifying TMED2, functional dimerization assays with phenotypic readouts, single lab\",\n      \"pmids\": [\"31040128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AGR2 dimerization involves K95-K95 adducts. The N-terminal intrinsically disordered region of AGR2 stabilizes dimer formation in trans. The AGR2 dimer (Δ45-AGR2, more stable) shows greater binding activity to its interacting protein Reptin than wild-type or monomeric AGR2(E60A). Dimer stability thus controls binding to Reptin.\",\n      \"method\": \"DSS-crosslinking assay, two-site sandwich microtiter assay with DyLight800-labeled antibody, AGR2 mutants (Δ45-AGR2 stable dimer; E60A monomer), Reptin binding assays\",\n      \"journal\": \"Protein science : a publication of the Protein Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — chemical crosslinking, mutagenesis, functional binding assay, single lab\",\n      \"pmids\": [\"23780840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Proteasome inhibition (MG132/bortezomib) suppresses AGR2 at mRNA and protein levels; MG132-mediated transcriptional repression is partially due to downregulation of E2F1. MG132 also facilitates degradation of polyubiquitinated AGR2 through autophagy activation via NBR1 as an autophagy receptor. The E3 ligase UBR5 conjugates K48-linked polyubiquitin chains onto K89 of AGR2.\",\n      \"method\": \"Pharmacological inhibitors (MG132, bortezomib, rapamycin), Atg5/Atg7 genetic depletion, K89 mutation, autophagy receptor (NBR1) knockdown, western blot, in vivo mouse samples\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — site-specific mutagenesis of ubiquitination site, genetic depletion of autophagy components, E3 ligase identification, single lab\",\n      \"pmids\": [\"30647455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AGR2 directs nuclear import of RNA Polymerase II (RNAPII) via its C-terminal nuclear localization signal and binds to the largest subunit of RNAPII in a peptide motif-dependent manner. This nuclear import undermines ATR-dependent p53 activation in acinar-to-ductal metaplasia lesions. A competitive hexapeptide disrupting the AGR2-RNAPII complex blocks RNAPII nuclear import and activates DNA damage response, dramatically compromising PDAC initiation in vivo.\",\n      \"method\": \"AGR2-RNAPII Co-immunoprecipitation, nuclear import assays, pancreas-specific Agr2 knockout mouse model, competitive hexapeptide in liposomes, patient-derived organoids, RNAPII inhibitor combination studies\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct protein-protein interaction, genetic KO model, competitive peptide disruption with mechanistic and in vivo functional validation\",\n      \"pmids\": [\"34303658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A homozygous missense variant in AGR2 in human patients causes infantile IBD (termed EAGLES). The mutant AGR2 shows reduced capacity to bind MUC2 (by co-immunoprecipitation) and reduced ability to alleviate tunicamycin-induced ER stress in HEK293T cells. Patient biopsies show reduced goblet cells, depletion of gel-forming mucins, and increased ER stress.\",\n      \"method\": \"Whole-genome sequencing, co-immunoprecipitation (AGR2-MUC2 binding with mutant vs. wild-type), ER stress assay in HEK293T cells with tunicamycin, immunohistochemistry of patient biopsies\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — human genetic variant with functional validation by Co-IP and ER stress assay, phenocopies AGR2-/- mouse, multiple orthogonal methods\",\n      \"pmids\": [\"34237462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Intracellular AGR2 binds to KDEL receptors (KDELRs) via its KTEL motif to activate downstream Gs-PKA signaling. Activated PKA upregulates NF-κB subunit c-Rel (REL) and acetylates histone H3 at K9 (H3K9ac), promoting transcription of SNAIL and SLUG to drive EMT and CRC metastasis. AGR2 is transcriptionally upregulated by prostaglandin E2 via the EP4-PI3K-AKT pathway.\",\n      \"method\": \"Co-immunoprecipitation (AGR2-KDELR), PKA activity assays, ChIP (H3K9ac), NF-κB reporter, SNAIL/SLUG expression, AGR2 promoter analysis with EP4 inhibitors\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional signaling assays with multiple readouts, single lab\",\n      \"pmids\": [\"34216690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tumour-associated neutrophil (TAN)-secreted AGR2 promotes CRC cell migration by binding the heavy chain of CD98 (CD98hc) as its functional receptor, increasing xCT activity in a CD98hc-dependent manner and activating the RhoA/ROCK2 cascade. Neutrophil-specific Agr2 knockout in mice reduced CRC liver metastases. CRC-derived TGF-β1 educates peripheral neutrophils to become AGR2+ TANs.\",\n      \"method\": \"Neutrophil-specific Agr2 knockout mice, Co-immunoprecipitation (AGR2-CD98hc), xCT activity assays, RhoA/ROCK2 signaling assays, orthotopic CRC models\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic KO model plus Co-IP receptor identification and downstream signaling characterization, multiple orthogonal methods\",\n      \"pmids\": [\"35086885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Oxidative stress-induced S-glutathionylation of AGR2 interferes with its processing and modification of MUC2 precursors, blocking synthesis of mature MUC2. NADPH (produced by G6PD) inhibits this S-glutathionylation and promotes AGR2 activity. Glutamine enhances G6PD O-GlcNAcylation, increasing G6PD homodimer formation and NADPH synthesis, which suppresses AGR2 S-glutathionylation.\",\n      \"method\": \"Burn-sepsis animal model, AGR2 S-glutathionylation assays, G6PD O-GlcNAc modification assays, G6PD homodimerization assay, NADPH measurement, MUC2 maturation assays\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — post-translational modification identified with functional consequences on AGR2 activity, single lab with multiple biochemical methods\",\n      \"pmids\": [\"36565645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AGR2 represses IRE1β UPR transducer activity in goblet cells. In vitro, AGR2 actively destabilizes the IRE1β luminal domain dimer and forms a reversible complex with the inactive monomer. Depletion of endogenous AGR2 from goblet cells induces spontaneous IRE1β activation. AGR2 mutants lacking catalytic cysteine or carrying disease-associated H117Y mutation failed to dampen IRE1β activity. Introduction of the goblet-cell client MUC2 reversed AGR2-mediated repression of IRE1β. AGR2 had no effect on IRE1α.\",\n      \"method\": \"IRE1β/α chimera in CHO cells, in vitro reconstitution (AGR2-IRE1β luminal domain interaction), AGR2 depletion in goblet cells, catalytic cysteine and H117Y mutants, MUC2 rescue experiment\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified domains, mutagenesis confirming catalytic requirement, independent replication across two papers (PMID 38177498 and 38177501) in same journal issue\",\n      \"pmids\": [\"38177498\", \"38177501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Zebrafish Agr2 is expressed specifically in intestinal goblet cells and is essential for their terminal differentiation. Morpholino knockdown results in accumulation of immature goblet cells containing few mucous granules. Notably, in contrast to mouse, agr2 knockdown in zebrafish did not extensively induce UPR pathway genes (hspa5, xbp1s, chop, atf4b1).\",\n      \"method\": \"Morpholino antisense knockdown, mRNA overexpression, fluorescent whole-mount in situ hybridization, transmission electron microscopy, ER stress marker qPCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino loss-of-function with TEM ultrastructural confirmation, single lab; negative ER stress result is mechanistically informative\",\n      \"pmids\": [\"22514630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RAD9A transcriptionally controls AGR2 by binding a partial p53 consensus sequence at position +3136 in the AGR2 5'-UTR, as demonstrated by ChIP and luciferase reporter assay. Mutation of the RAD9A-binding sequence abolished luciferase activity. Ectopic AGR2 expression in RAD9A-depleted cells restored cell migration and anchorage-independent growth phenotypes.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with binding-site mutation, stable/transient RAD9A knockdown, rescue by ectopic AGR2 expression\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct promoter occupancy by ChIP plus mutant reporter plus epistasis rescue, single lab\",\n      \"pmids\": [\"30295739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AGR2 binds to MUC1 and induces MUC1 and HIF-1α expression in endometrial cancer cells. The pro-proliferative, migratory, and glycolytic effects of AGR2 are abolished by MUC1 knockdown, placing MUC1 downstream of AGR2 in the AGR2/MUC1/HIF-1α axis.\",\n      \"method\": \"Co-immunoprecipitation (AGR2-MUC1), MUC1 overexpression rescue of AGR2 knockdown, glycolysis assays, xenograft model\",\n      \"journal\": \"Human cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus epistasis rescue experiment, single lab\",\n      \"pmids\": [\"32304027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AGR2 expression in breast cancer requires both FOXA1 and ERα for transcriptional regulation in tamoxifen-sensitive cells. In tamoxifen-resistant cells, constitutive AGR2 expression requires FOXA1 but loses ERα dependence, indicating a FOXA1-ERα-AGR2 regulatory loop disrupted during endocrine resistance.\",\n      \"method\": \"AGR2 knockdown in tamoxifen-sensitive and -resistant breast cancer cells, FOXA1/ERα siRNA knockdown, in vivo xenograft tumor growth, migration assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (FOXA1/ERα double KD), in vivo validation, single lab\",\n      \"pmids\": [\"25100862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"shRNA-mediated knockdown of AGR2 or ERp44 enhances basal DR5 oligomerization. AGR2 and ERp44 are identified as targets of Disulfide bond Disrupting Agents (DDAs) by biotinylated-DDA affinity purification, and their inhibition triggers DR4/DR5 disulfide-mediated oligomerization and caspase-8 activation in breast cancer cells.\",\n      \"method\": \"Biotinylated-DDA affinity purification, shRNA knockdown of AGR2/ERp44, DR5 oligomerization assays, ERp44 mutant expression, caspase-8 activation assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity purification identifies AGR2 as DDA target, genetic KD with functional DR5 oligomerization readout, single lab\",\n      \"pmids\": [\"35247515\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AGR2 is an ER-resident protein disulfide isomerase that forms mixed disulfide bonds with gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC1) to enable their proper folding and secretion; acts as a sequence-specific peptide-binding chaperone (TTIYY motif) for client proteins including EpCAM; represses IRE1β UPR signaling in goblet cells by binding and destabilizing its luminal domain dimer; promotes nuclear import of RNA Polymerase II via its C-terminal NLS; signals intracellularly through KDEL receptors to activate Gs-PKA and downstream transcription of EMT drivers; when secreted (facilitated by C81S modification or KTEL deletion), acts extracellularly through receptors C4.4A and CD98hc to activate non-canonical Wnt, RhoA/ROCK2, and NF-κB signaling cascades promoting invasion and metastasis; and is regulated post-translationally by S-glutathionylation and K48-linked ubiquitination (by E3 ligase UBR5) at K89 with autophagic clearance via NBR1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AGR2 is an endoplasmic reticulum-resident protein disulfide isomerase that enables the folding and secretion of gel-forming mucins and other secretory clients, and whose function is essential for goblet cell biology and intestinal mucus production [#0, #1]. It engages mucins both covalently and non-covalently: it forms mixed disulfide bonds with MUC2 through a cysteine in its thioredoxin-like domain in intestinal epithelium [#0], complexes with immature airway mucins MUC5AC/MUC5B [#8], and acts as a chaperone for the cancer mucin MUC1 [#9, #32]. Client recognition is sequence-specific—AGR2 binds a TTIYY-type peptide motif through a structural loop (residues 131-135), the basis for its stable interaction with EpCAM [#19]. AGR2 expression is induced by ER stress and its loss elevates the unfolded protein response and disrupts ER-associated degradation [#1, #5]; mechanistically, AGR2 directly represses the goblet-cell UPR transducer IRE1\\u03b2 by destabilizing its luminal-domain dimer in a manner reversed by the client mucin MUC2, an activity requiring its catalytic cysteine [#29]. Retention in the ER depends on a specific KTEL motif, and loss of this motif or modification of its single cysteine (C81S) shifts AGR2 to a secreted, extracellular form (eAGR2) with distinct, often opposing functions [#7, #10, #13, #20]. Intracellular AGR2 signals through KDEL receptors to activate Gs-PKA and drive transcription of EMT regulators SNAIL/SLUG [#26] and promotes EGFR trafficking and YAP1-dependent proliferation and tissue regeneration [#6, #15]; it also directs nuclear import of RNA Polymerase II via a C-terminal NLS to suppress p53/DNA-damage responses during pancreatic tumor initiation [#24]. Secreted AGR2 acts through cell-surface receptors C4.4A and CD98hc to activate non-canonical Wnt, RhoA/ROCK2 and other pro-invasive cascades and modulates the extracellular matrix to promote invasion and metastasis [#12, #27, #17, #13]. AGR2 dimerization, enhanced by TMED2 and mediated by lysine adducts, governs ER homeostasis versus inflammatory secretion [#21, #22], and the protein is regulated post-translationally by S-glutathionylation that blocks MUC2 maturation [#28] and by UBR5-mediated K48 ubiquitination at K89 with autophagic clearance via NBR1 [#23]. A homozygous AGR2 missense variant that impairs MUC2 binding and ER-stress relief causes an infantile inflammatory bowel disease (EAGLES) in humans, phenocopying the AGR2-null mouse [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"The first candidate AGR2 interactors were identified, raising the possibility that this protein engages cell-surface and metastasis-associated partners.\",\n      \"evidence\": \"Yeast two-hybrid screen identifying C4.4A and alpha-dystroglycan\",\n      \"pmids\": [\"12592373\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Y2H only, no Co-IP or pulldown validation in mammalian cells\", \"Functional significance of binding not established\", \"Did not distinguish intracellular vs extracellular interaction\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that AGR2 has oncogenic activity rather than being merely a marker, by showing it drives transformation and tumor growth.\",\n      \"evidence\": \"RNAi and stable overexpression in cell lines with xenograft and anchorage-independent growth assays\",\n      \"pmids\": [\"18199544\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of transformation not defined\", \"Did not address ER-resident vs secreted contributions\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined AGR2's core physiological function as an ER-resident enzyme that covalently processes mucins and is essential for mucus production, answering what AGR2 does in normal epithelium.\",\n      \"evidence\": \"ER fractionation, mixed disulfide detection with MUC2, and AGR2-null mouse phenotype; siRNA and inducible/germline knockouts linking AGR2 to ER stress and Paneth cells\",\n      \"pmids\": [\"19359471\", \"20025862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise cysteine residue and disulfide partner geometry on MUC2 not fully mapped\", \"Range of mucin clients beyond MUC2 not yet defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected AGR2's ER chaperone role to broader ER proteostasis and to oncogenic signaling outputs, and showed the KTEL retention motif itself is required for intracellular function.\",\n      \"evidence\": \"Proteomics of ER membrane-bound ribosomes and ERAD components; AREG/YAP1 and CTSB/CTSD downstream effects; KTEL deletion/substitution mutants with functional reporters\",\n      \"pmids\": [\"22025610\", \"21948970\", \"21454516\", \"22184114\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How the specific KTEL sequence (vs KDEL/KSEL) confers function was not mechanistically resolved at this stage\", \"Direct vs indirect engagement of nascent chains unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Generalized the mucin-chaperone role across tissues and species and to cancer-associated mucins, showing conservation of AGR2's secretory function.\",\n      \"evidence\": \"Co-IP with immature MUC5AC and airway Agr2-/- model; MUC1 gain/loss in pancreatic cancer with SMAD4-dependent regulation; zebrafish morpholino goblet-cell differentiation\",\n      \"pmids\": [\"22403803\", \"22945649\", \"22514630\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Zebrafish data showed UPR induction is not universally coupled to AGR2 loss, indicating species/context differences\", \"Direct vs indirect MUC1 chaperoning not fully separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a biochemical switch—single-cysteine modification (C81S)—that permits AGR2 secretion past the KTEL signal, establishing how AGR2 escapes the ER.\",\n      \"evidence\": \"Mucus fractionation and CHO-K1 secretion assays with C81S mutant; negative covalent MUC2-terminus binding result\",\n      \"pmids\": [\"25111734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological trigger for C81 modification in vivo not identified\", \"Apparent conflict with covalent MUC2 binding data not reconciled\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a receptor-based mechanism for extracellular AGR2, showing it signals through C4.4A to promote malignant phenotypes, and described an intracellular pro-survival pathway suppressing p53.\",\n      \"evidence\": \"Reciprocal Co-IP with recombinant proteins, C4.4A knockdown and blocking antibodies, orthotopic xenografts; DUSP10/p38/p53 pathway dissection\",\n      \"pmids\": [\"25646014\", \"26733232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-receptor requirements (laminin/integrin) not fully mechanistically dissected\", \"Generality of C4.4A axis across cancer types untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that secreted AGR2 is sufficient on its own, independent of its catalytic and retention domains, to confer invasive/metastatic features and to remodel the microenvironment.\",\n      \"evidence\": \"Domain-deletion mutants, ECM interaction and 3D morphogenesis assays, invasion/metastasis assays; FOXM1 ChIP and reporter with transgenic models defining transcriptional control\",\n      \"pmids\": [\"27240165\", \"29267283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Extracellular receptor(s) for catalytic-independent eAGR2 activity in this system not specified\", \"ECM-binding partners unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed AGR2 within EMT control and tissue regeneration, showing context-dependent (intracellular) roles in EGFR trafficking and epithelial identity.\",\n      \"evidence\": \"Caerulein pancreatitis in Agr2-/- mice with EGFR localization and inhibitor studies; TGF-\\u03b2/Smad/ERK regulation of AGR2 with CRISPR/siRNA EMT readouts\",\n      \"pmids\": [\"27764193\", \"28810836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism of AGR2-driven EGFR trafficking not defined\", \"Whether EMT effects are intracellular vs secreted AGR2 not cleanly separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped multiple receptor and signaling outputs for secreted and cytosolic AGR2, distinguishing localization-dependent, often opposing, functions.\",\n      \"evidence\": \"Wnt11/CaMKII/JNK dissection; recombinant VEGFA disulfide binding and p65/NF-\\u03baB Co-IP; mTORC2/RICTOR phosphorylation with localization mutants and metastasis models\",\n      \"pmids\": [\"29427622\", \"29410027\", \"30575818\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Opposing iAGR2 vs eAGR2 effects on Hippo/mTORC2 mechanistically incompletely resolved\", \"Single-lab pathway assignments not cross-validated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the structural basis of AGR2 client recognition, establishing it as a sequence-specific peptide-binding chaperone.\",\n      \"evidence\": \"HDX-MS structural mapping, peptide affinity purification, mutant peptide library, PLA and in vitro binding with EpCAM Tyr251 mutant\",\n      \"pmids\": [\"29339412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full client repertoire bearing the TTIYY motif not enumerated\", \"Co-existence of covalent disulfide and non-covalent peptide recognition not unified structurally\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established that AGR2 dimerization state is a regulatory switch between ER homeostasis and inflammatory secretion, and defined its post-translational degradation route.\",\n      \"evidence\": \"TMED2 interaction screen and dimerization assays with IBD tissue; DSS-crosslinking, K95 adduct and Reptin binding mutants; UBR5/K89 ubiquitination, NBR1-autophagy and proteasome-inhibitor studies; RAD9A transcriptional control\",\n      \"pmids\": [\"31040128\", \"23780840\", \"30647455\", \"30295739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How dimerization is sensed and reversed in vivo unclear\", \"Relationship between K89 ubiquitination, K95 dimer adducts, and secretion not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed unexpected nuclear and KDELR-coupled signaling functions, showing AGR2 controls RNAPII import and PKA-driven EMT transcription, and confirmed human disease causation.\",\n      \"evidence\": \"AGR2-RNAPII Co-IP, nuclear import assays, pancreas-specific KO and competitive hexapeptide; AGR2-KDELR Co-IP with PKA/NF-\\u03baB/H3K9ac readouts; whole-genome sequencing of EAGLES patients with functional MUC2-binding and ER-stress validation\",\n      \"pmids\": [\"34303658\", \"34216690\", \"34237462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same KTEL motif serves both KDELR signaling and ER retention not fully reconciled\", \"Structural basis of RNAPII NLS-mediated import undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended AGR2 biology to the tumor microenvironment and defined CD98hc as an extracellular receptor, plus a redox post-translational control of mucin maturation.\",\n      \"evidence\": \"Neutrophil-specific Agr2 KO, AGR2-CD98hc Co-IP, xCT/RhoA/ROCK2 assays; AGR2 S-glutathionylation and G6PD/NADPH axis in burn-sepsis model; AGR2/ERp44 as DDA targets controlling DR5 oligomerization; AGR2-MUC1-HIF1\\u03b1 axis\",\n      \"pmids\": [\"35086885\", \"36565645\", \"35247515\", \"32304027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cross-talk between AGR2's pro-survival disulfide functions and apoptosis (DR5) needs integration\", \"In vivo relevance of S-glutathionylation beyond burn-sepsis model untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved a direct mechanism by which AGR2 governs the goblet-cell UPR, showing it actively represses IRE1\\u03b2 and links client load to UPR signaling.\",\n      \"evidence\": \"IRE1\\u03b2/\\u03b1 chimeras in CHO cells, in vitro reconstitution of AGR2-IRE1\\u03b2 luminal-domain destabilization, catalytic-cysteine and H117Y mutants, MUC2 rescue; independent replication across two papers\",\n      \"pmids\": [\"38177498\", \"38177501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of AGR2 destabilizing the IRE1\\u03b2 dimer not fully resolved\", \"How disease mutations alter this specific repression in vivo not directly tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AGR2's multiple, sometimes opposing, intracellular (ER chaperone, IRE1\\u03b2 repressor, KDELR signaler, RNAPII importer) and extracellular (C4.4A/CD98hc receptor agonist) activities are coordinated by localization, dimerization, and redox state within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking modification state (C81/C95/K89, glutathionylation) to functional partitioning\", \"Structural basis for nuclear import and KDELR signaling undefined\", \"Receptor specificity determinants for eAGR2 not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016853\", \"supporting_discovery_ids\": [0, 29]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [8, 9, 19, 29]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 19, 29]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [12, 26, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [29, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 1, 5, 8]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [10, 13, 12, 27]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 8, 9, 19]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [1, 5, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 17, 26, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 2, 24]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [24, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MUC2\", \"MUC5AC\", \"MUC1\", \"EpCAM\", \"IRE1B\", \"C4.4A\", \"CD98hc\", \"TMED2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}